Tirzepatide & Semaglutide: Groundbreaking Heart Protection
Tirzepatide, known for its effectiveness in reducing blood sugar and aiding weight loss through its dual GLP-1 and GIP receptor agonist action, previously lacked direct evidence of cardiovascular protection in real-world scenarios. While SURPASS trials highlighted its glucose-lowering and weight-loss effects, extensive data on cardiovascular outcomes was still needed. ("Tirzepatide Once weekly for the Treatment of Type 2 Diabetes").Study Design: A Real-World Data Approach
Researchers at Mass General Brigham, under the guidance of Dr. Nils Krüger, examined information from a comprehensive national health insurance database. This database included nearly one million adults diagnosed with type 2 diabetes between January 1, 2018, and December 31, 2022. The study centered on individuals who began treatment using either tirzepatide, semaglutide, or sitagliptin, a commonly prescribed DPP-4 inhibitor. Dr. Krüger explained that while randomized controlled trials are often considered the gold standard in medical evidence, they aren't always feasible for answering every question. He added that data from clinical practice allows researchers to efficiently address a wide range of relevant clinical questions. Health tracking apps like Shotlee can help monitor these data points. Furthermore, it allows for studying patients who represent everyday clinical care, unlike the highly selective participants in randomized experiments.The primary outcome assessed was a combination of major adverse cardiovascular events (MACE), specifically heart attack, stroke, and cardiovascular death. The researchers accounted for various factors that could impact cardiovascular risk, including age, sex, race, pre-existing conditions, and other medications.
